

Literaturverzeichnis

zum Artikel „Aktuelle Möglichkeiten in der HIV-Prävention“

von Dr. Christoph D. Spinner, Christiane Schwerdtfeger, Marcel Lee und Dr. Alexander Zink, Bayerisches Ärzteblatt 10/2016, Seite 518 ff.

1. RKI - Epidemiologisches Bulletin Nr. 26 [Internet]. [cited 2015 Aug 16]. Available from: https://www.rki.de/DE/Content/Infekt/EpidBull/Archiv/2014/Ausgaben/26_14.pdf?__blob=publicationFile
2. Druce JD, Jardine D, Locarnini SA, Birch CJ. Susceptibility of HIV to inactivation by disinfectants and ultraviolet light. *J Hosp Infect.* 1995 Jul;30(3):167–80.
3. Benn P, Sultan B, Waters L. Current perspectives in HIV post-exposure prophylaxis. *HIV.* 2014 Oct;;147.
4. Wyzgowski P, Rosiek A, Grzela T, Leksowski K. Occupational HIV risk for health care workers: risk factor and the risk of infection in the course of professional activities. *Ther Clin Risk Manag.* 2016;12:989–94.
5. EACS Guidelines 8.0 [Internet]. [cited 2016 Mar 19]. Available from: http://www.eacsociety.org/files/2015_eacsguidelines_8_0-english_rev-20160124.pdf
6. May M, Gompels M, Sabin C. Life expectancy of HIV-1-positive individuals approaches normal conditional on response to antiretroviral therapy: UK Collaborative HIV Cohort Study. *Journal of the International AIDS Society.* 2012;15 Suppl 4:18078.
7. Spinner CD. [Simplification of antiviral therapy with single tablet regimens: advantages and disadvantages of modern ART]. *MMW Fortschr Med.* 2014 Jun 12;156 Suppl 1:29–32.
8. Lee FJ, Amin J, Carr A. Efficacy of initial antiretroviral therapy for HIV-1 infection in adults: a systematic review and meta-analysis of 114 studies with up to 144 weeks' follow-up. *PLoS ONE.* 2014;9(5):e97482.
9. Llibre JM, Walmsley S, Gatell JM. Backbones versus core agents in initial ART regimens: one game, two players. *Journal of Antimicrobial Chemotherapy.* 2016 Apr;71(4):856–61.
10. INSIGHT START Study Group. Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection. *N Engl J Med.* 2015 Jul 20.
11. Cohen MS, McCauley M, Gamble TR. HIV treatment as prevention and HPTN 052. *Current Opinion in HIV and AIDS.* 2012 Mar;7(2):99–105.
12. Bryant J, Baxter L, Hird S. Non-occupational postexposure prophylaxis for HIV: a systematic review. *Health Technol Assess.* 2009 Feb;13(14):iii–ix–x–1–60.
13. Ford N, Shubber Z, Calmy A, Irvine C, Rapparini C, Ajose O, et al. Choice of Antiretroviral Drugs for Postexposure Prophylaxis for Adults and Adolescents: A Systematic Review. *Clin Infect Dis.* 2015 May 13;60(suppl 3):S170–6.
14. Spinner CD, Boesecke C, Zink A, Jessen H, Stellbrink H-J, Rockstroh JK, et al. HIV pre-exposure prophylaxis (PrEP): a review of current knowledge of oral systemic HIV PrEP in humans. *Infection.* Springer Berlin Heidelberg; 2015 Oct 14;;1–8.

15. Anderson PL, Glidden DV, Liu A, Buchbinder S, Lama JR, Guanira JV, et al. Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men. *Sci Transl Med*. 2012 Sep 12;4(151):151ra125.
16. Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, et al. Preexposure Chemoprophylaxis for HIV Prevention in Men Who Have Sex with Men. *N Engl J Med*. 2010 Dec 30;363(27):2587–99.
17. Molina JM, Capitant C, Charreau I, et al. On demand PrEP with oral TDF/FTC in MSM: results of the ANRS Ipergay trial. Program and abstracts of the 2015 Conference on Retroviruses and Opportunistic Infections; February 23-26, 2015; Seattle, Washington. Abstract 23LB.